Leerink Partners Downgrades Shockwave Medical to Market Perform, Lowers Price Target to $335
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Mike Kratky downgraded Shockwave Medical (SWAV) from Outperform to Market Perform and reduced the price target from $361 to $335.
April 08, 2024 | 6:24 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Shockwave Medical was downgraded by Leerink Partners from Outperform to Market Perform, with a price target reduction from $361 to $335.
The downgrade from Outperform to Market Perform by a reputable analyst firm like Leerink Partners, coupled with a significant reduction in price target, is likely to negatively impact investor sentiment towards SWAV in the short term. This could lead to a decrease in stock price as market participants adjust their expectations based on the new analyst rating and price target.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100